Abstract:Cancer-derived exosomes have recently emerged as potent candidates for diagnosis and prognosis of breast cancer. As an example, programmed death ligand-1 positive (PD-L1+) exosomes are found to be correlated with the progression and immunotherapy response of breast cancer, and therefore show great potential in liquid biopsy. Herein, we propose an electrochemical biosensing method for accurate identification of PD-L1+ exosomes by using DNA amplification-responsive metal-organic frameworks, @ZIF-8. Specially, PD-L1+ exosomes are captured by anti-CD63 functionalized magnetic beads and bound with anti-PD-L1-linked capture probe. Then, in situ hyperbranched rolling circle amplification, a typical DNA amplification reaction, is conducted using the surface-attached capture probes as primers, which lows environmental pH. As a result, disassembly of @ZIF-8 takes place, leading to the release of enzymes, which can arouse amplified electrochemical responses for the identification of target exosomes. Experimental results reveal that the biosensing method displays a linear range for PD-L1+ exosomes identification from 1 × 103 to 1 × 1010 particles/mL and the detection limit reaches 334 particles/mL. What is more, by using the method, elevated level of circulating PD-L1+ exosomes is found in the undiluted serum samples from patients with breast cancer, particularly for metastatic breast cancer, revealing a positive correlation of the PD-L1+ exosome level with the tumor staging and disease progression of breast cancer. Therefore, the biosensing method may be valuable for not only exosome identification but also providing reference information for diagnosis and real-time monitoring of breast cancer in the future.

A PLA-mediated transistor biosensor enables specific identification of tumor-derived exosomal PD-L1

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Target proteins-regulated DNA nanomachine-electroactive substance complexes enable separation-free electrochemical detection of clinical exosome

Triple-color fluorescence co-localization of PD-L1-overexpressing cancer exosomes

Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks

Programmable DNA Circuit-Facilitated Determination of Circulating Extracellular Vesicle PD-L1 for Lung Cancer Diagnosis and Immunotherapy Response Prediction.

APPROACH: Sensitive Detection of Exosomal Biomarkers by Aptamer-Mediated Proximity Ligation Assay and Time-Resolved Förster Resonance Energy Transfer

Selective Enrichment and Detection of PD-L1 Positive Extracellular Vesicles Derived from Human Plasma and Patient Derived Tumor Cells

Integrated microfluidic system for isolating exosome and analyzing protein marker PD-L1

Tracing Tumor‐Derived Exosomal PD‐L1 by Dual‐Aptamer Activated Proximity‐Induced Droplet Digital PCR

Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response

Integrated FET sensing microsystem for specific detection of pancreatic cancer exosomal miRNA10b

An Electrochemical Biosensor for PD-L1 Positive Exosomes Based on Ultra-Thin Two-Dimensional Covalent Organic Framework Nanosheets Coupled with CRISPR-Cas12a Mediated Signal Amplification

Aptamer-Cholesterol-Mediated Proximity Ligation Assay for Accurate Identification of Exosomes.

Simultaneous Detection of Exosomal Membrane Protein and RNA by Highly Sensitive Aptamer Assisted Multiplex-PCR.

Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker

Programmable DNA-Fueled Electrochemical Analysis of Lung Cancer Exosomes

Trace Analysis of Multiple Tumor Exosomal PD‐L1 Based on SERS Immunoassay Platform

Accurate and rapid quantification of PD-L1 positive exosomes by a triple-helix molecular probe

An easy-operation aptasensor for simultaneous detection of multiple tumor-associated exosomal proteins based on multicolor fluorescent DNA nanoassemblies

Applying CRISPR/Cas13 to Construct Exosomal PD-L1 Ultrasensitive Biosensors for Dynamic Monitoring of Tumor Progression in Immunotherapy